The company is moving ahead with development plans after seeing positive data from a Phase I/II trial testing the diagnostic in neuroendocrine tumors.

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and ...

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

Rare Therapeutics will specifically advance gene therapies for extremely rare diseases with a goal of making them accessible globally.

Previously, the agency recommended doctors only discuss the risk of adverse events from chemotherapy for those with DPD deficiency.

The company expects topline results in 2026 from this group of the basket trial testing the drug plixorafenib as a ...

Although the committee was uncertain about some of the evidence, it found that Lorviqua's cost-effectiveness was an acceptable use of NHS resources.

A retrospective study using data from multiple trials could provide regulators evidence on Ataraxis Breast's ability to predict treatment response.

The firm will use the funds to move its gene therapy for BAG3-associated dilated cardiomyopathy toward the clinic, among other pipeline candidates.

Patients with advanced triple-negative breast cancer who are ineligible for immunotherapy survived longer on Datroway than chemotherapy.

Arbor will receive $115 million in upfront and near-term payments and be eligible for up to $2 billion in milestone payments and tiered royalties.